Estudo randomizado | Ustequinumabe vs. adalimumabe para terapia de indução e de manutenção em pacientes virgens de biológicos com doença de Crohn ativa moderada a grave.

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário no Twitter

New @TheLancet – Sands et al – Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE trial)https://t.co/Ov9ahRTQuC#IBD #GITwitter #Crohnsdisease pic.twitter.com/5f3vI6rRKd

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 10, 2022